{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T11:00:54Z","timestamp":1774090854362,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapies are at increased risk of vaccine-preventable diseases, including influenza. Despite recommendations for annual influenza vaccination, uptake remains suboptimal. The COVID-19 pandemic prompted a surge in telemedicine (Tele-M) use, raising concerns about its impact on vaccination rates due to reduced in-person interactions. This study aimed to assess the impact of IBD-specific Tele-M on influenza vaccine uptake and identify predictors of vaccination in patients with IBD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This single-center retrospective study evaluated influenza vaccine uptake among adult patients with IBD seen between September 2021 and April 2022. Patients were categorized into two groups: Tele-M only and \u22651 in-person visit. Vaccination status was confirmed using the Wisconsin Immunization Registry. Primary outcome was influenza vaccination frequency by visit type, while secondary outcomes evaluated the impact of Tele-M on other vaccinations and predictors of influenza vaccine uptake.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 547 patients, 53.2% received Tele-M only and 46.8% had \u22651 in-person visit. Influenza vaccine uptake was similar between the Tele-M only and \u22651 in-person visit groups (69.0% vs. 75.1%, respectively, p\u2009=\u20090.11). The uptake of pneumococcal, hepatitis B, and zoster vaccines was also comparable. Predictors of higher influenza vaccine uptake included age \u226565, female sex, receipt of\u2009\u2265\u20093 COVID-19 vaccines, and previous influenza vaccination.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n IBD-specific Tele-M did not adversely affect influenza vaccine uptake among patients with IBD. These findings highlight the importance of ensuring vaccination compliance irrespective of healthcare delivery modes. Collaboration among healthcare providers is crucial to improve vaccination rates in patients with IBD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/crocol\/otag022","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:23:08Z","timestamp":1774088588000},"source":"Crossref","is-referenced-by-count":0,"title":["Influenza Vaccine Uptake Among Patients with Inflammatory Bowel Disease: Comparable Outcomes Between Telemedicine and In-Person Care"],"prefix":"10.1093","author":[{"given":"Mazen","family":"Almasry","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , Department of Internal Medicine, Madison, Wisconsin,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor L","family":"Schell","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , Department of Internal Medicine, Division of Gastroenterology and Hepatology, Madison, Wisconsin,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Richard","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , Department of Internal Medicine, Madison, Wisconsin,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Gastroenterology and Hepatology, , Jacksonville, Florida,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary S","family":"Hayney","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , School of Pharmacy, Madison, Wisconsin,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Caldera","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health , Department of Internal Medicine, Division of Gastroenterology and Hepatology, Madison, Wisconsin,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,21]]},"container-title":["Crohn's & Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag022\/67457101\/otag022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag022\/67457101\/otag022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:23:08Z","timestamp":1774088588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article\/doi\/10.1093\/crocol\/otag022\/8533302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag022","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"article-number":"otag022"}}